Clinical Trials Logo

Filter by:
NCT ID: NCT05839106 Recruiting - Advanced Tumor Clinical Trials

Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors

Start date: July 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose(RP2D) of PM1032.

NCT ID: NCT05838755 Recruiting - Pain Clinical Trials

A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

NEPTUNE-17
Start date: September 20, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.

NCT ID: NCT05838742 Recruiting - Pain Clinical Trials

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis Pain

MARS-17
Start date: September 13, 2023
Phase: Phase 2
Study type: Interventional

This is dose-finding study of GSK3858279 in participants with moderate to severe knee osteoarthritis (OA) pain. The purpose of this study is to investigate and provide the data necessary to select the optimal effective and safe dose(s) of GSK3858279.

NCT ID: NCT05838573 Recruiting - Schizophrenia Clinical Trials

Metformin Treatment on Cognitive Impairment of Schizophrenia

Start date: May 8, 2023
Phase: Phase 3
Study type: Interventional

In this study, the investigators will investigate the effect and the underlying mechanism of metformin treatment on cognitive impairment in individuals with schizophrenia. The study will recruit 120 individuals with schizophrenia at 4 sites, who will be randomized to metformin or placebo group for 24-week treatment. Clinical assessments will be done at screen/baseline, 12th week and 24th week. Participants who don't meet any of the diagnostic criteria for metabolic syndrome will only accept baseline evaluations. The specific aims are to compare healthy volunteers versus schizophrenic participants on:1) cognition; 2) MRI features, and to compare metformin group versus placebo group of 24-week treatment cohort on: 1) cognition; 2) clinical core symptoms; 3) MRI features. Biological samples also will be collected and stored to explore related mechanisms.

NCT ID: NCT05838183 Recruiting - ILD OSA Clinical Trials

Interstitial Lung Disease and Obstructive Sleep Apnea

Start date: April 1, 2023
Phase:
Study type: Observational

Clinically, all patients with interstitial lung disease were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the ROSE smear was evaluated, combined with the NGS results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease. Patients with apnea should be tested for polysomnography, and corresponding biological specimens should be obtained for molecular biology or other tests

NCT ID: NCT05838157 Recruiting - Clinical trials for Premature Ovarian Failure

The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age

Start date: May 4, 2023
Phase:
Study type: Observational

Cervical cancer is one of the most common cancer in women, making it the fourth largest cause of female cancer mortality worldwide. High-risk HPV types (hrHPV) continuous infection is the main cause of the premalignant and malignant lesions of the cervix. The most effective primary prevention of cervical cancer is administration HPV vaccines. There are three prophylactic HPV vaccines including bivalent HPV (2vHPV), quadrivalent HPV vaccine (4vHPV),9-valent HPV vaccine (9vHPV) currently. With the widespread of HPV vaccination, the cases related to abnormal menstrual cycle or menstrual irregularities has gradually increased in the Vaccine Adverse Event Reporting System, also the number of reports and studies were increasing. We designed this study to evaluate the statistical association of HPV vaccine and changes in menstrual cycle or menstrual irregularities、amenorrhea. And detect the signal of premature ovarian insufficiency (POI) and related events of three HPV vaccines, and to provide evidence for the safety of HPV vaccines based on the data mining and signal detection method. The research data was obtained from prospective self- developed questionnaire. Before-after study was applied in this study, investigators collect the menstrual cycle data of subjects by the questionnaire and qualitatively interview were taken. The control group is before vaccination, HPV vaccination is Intervention group.

NCT ID: NCT05838131 Recruiting - Multiple Myeloma Clinical Trials

Study of CT071 Injection in RRMM or PPCL

Start date: April 28, 2023
Phase: Early Phase 1
Study type: Interventional

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

NCT ID: NCT05838118 Recruiting - CKD Clinical Trials

Washed Microbiota Transplantation (WMT) for Chronic Kidney Disease (CKD)

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

Wahsed microbiota transplantation (WMT) is a novel and promising therapeutic method for Chronic Kidney Disease (CKD). This clinical trail aims to evaluate the efficacy and safety of WMT in the treatment of CKD.

NCT ID: NCT05838053 Recruiting - Lung Adenocarcinoma Clinical Trials

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Start date: August 20, 2019
Phase:
Study type: Observational

This study aims to evaluate the superiority in recurrence-free survival of lobectomy compared with segmentectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype positive by intraoperative frozen sections.

NCT ID: NCT05838001 Recruiting - Breast Cancer Clinical Trials

Efficacy and Accuracy of Combined Localization Versus Single Localization in Non-palpable Breast Cancer After Neoadjuvant Therapy

Start date: February 16, 2023
Phase: N/A
Study type: Interventional

The standard method for localizing non-palpable breast cancer is currently clip localization, its positive margin rate still remains around 20-50%. This study aims to compare the accuracy and efficacy of single vs. combined breast tissue markers in localizing non-palpable breast cancer.